Biotechnology Value Fund L P SC 13G PIERIS PHARMACEUTICALS / BIOTECHNOLOGY VALUE FUND L P ownership change

Exhibit 99.1

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated May 17, 2024 with respect to the Common Stock, $0.001 par value per share, of Pieris Pharmaceuticals, Inc., a Nevada corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: May 17, 2024

BIOTECHNOLOGY VALUE FUND, L.P.		BIOTECHNOLOGY VALUE TRADING FUND OS LP
By:	BVF I GP LLC, its general partner
		By:	BVF Partners L.P., its investment manager
By:	/s/ Mark N. Lampert	By:	BVF Inc., its general partner
	Mark N. Lampert
	Chief Executive Officer	By:	/s/ Mark N. Lampert
			Mark N. Lampert
			President
BVF I GP LLC
By:	/s/ Mark N. Lampert	BVF GP HOLDINGS LLC
	Mark N. Lampert
	Chief Executive Officer	By:	/s/ Mark N. Lampert
			Mark N. Lampert
			Chief Executive Officer
BIOTECHNOLOGY VALUE FUND II, L.P.
By:	BVF II GP LLC, its general partner	BVF PARTNERS L.P.
By:	/s/ Mark N. Lampert	By:	BVF Inc., its general partner
	Mark N. Lampert
	Chief Executive Officer	By:	/s/ Mark N. Lampert
			Mark N. Lampert
			President
BVF II GP LLC
By:	/s/ Mark N. Lampert	BVF INC.
	Mark N. Lampert
	Chief Executive Officer	By:
			Mark N. Lampert
			President
BVF PARTNERS OS LTD.
By:	BVF Partners L.P., its sole member	/s/ Mark N. Lampert
By:	BVF Inc., its general partner	MARK N. LAMPERT
By:	/s/ Mark N. Lampert
	Mark N. Lampert
	President